Inspira Outlines Strategic Vision and Transaction Framework for Breast Cancer Liquid Biopsy Expansion

Stock Information for Inspira Technologies Oxy B.H.N. Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inspira Technologies Oxy B.H.N. Ltd.

ART100 Becomes Inspira's First System to Complete Clinical Evaluation and Enters Budgeted Procurement at Top U.S. Medical Center
Inspira Advances to Final Governmental Budgetary Validation Procedures for Previously Announced Binding Purchase Orders
CORRECTION - Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Investment of $15 Million into Inspira at $180 Million Valuation
Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation
Inspira Technologies Reaffirms $49.5 Million in Binding Purchase Orders and Aligns Execution with 2026 Regulatory and Deployment Milestones
Inspira Announces $1.8 Million Registered Direct Offering Priced At-The-Market and Additional Equity Financing Agreement to Support Ongoing Commercial Execution
Inspira Technologies Granted Patent in Japan for the INSPIRA(TM) ART System's Convertible Dual Lumen Cannula Device and Method of Use
Inspira Technologies Announces Strategic Leap in Lab Capabilities - Accelerating Next-Generation Diagnostics and Blood Technology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.